The United Kingdom government has terminated the contract with Valneva due to an alleged breach of contract, the company announced Monday.
“The contract provides HMG with the right to terminate. HMG has alleged that the company is in breach of its obligations under the Supply Agreement, but the company strenuously denies this,” Valvena said in a statement.
Britain had placed an initial order for 100 million doses of Valneva’s vaccine candidate, VLA2001, with an option to purchase an additional 90 million doses.
The total cost of these 190 million doses is estimated to be approximately €1.4 billion.
Meanwhile, Scotland’s health secretary, Humza Yousaf, said they would be reaching out to the company to get security and secure a future for that facility in Livingston.
“This is a blow for the facility in Livingston. We are very keen and will be reaching out to the company to try to get security and secure a future for that facility in Livingston; we hope that would be with Valneva,” Yousaf said.
“Clearly, when it comes to their supposed alleged failure to meet their contract obligations, we obviously are looking for more information from the UK government and would expect that shortly,” Yousaf added.
Valvena said it had worked “tirelessly” on the collaboration with HMG.
“Valneva has worked tirelessly, and to its best efforts, on the collaboration with HMG, including investing significant resources and effort to respond to HMG’s requests for variant-derived vaccines,” the company said.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.